Last update Oct. 29, 2024
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Brompheniramine Maleate is also known as
Brompheniramine Maleate in other languages or writings:
Brompheniramine Maleate belongs to this group or family:
Main tradenames from several countries containing Brompheniramine Maleate in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 100 | % |
Molecular weight | 435 | daltons |
VD | 11.7 | l/Kg |
pKa | 3.9 | - |
Tmax | 3 | hours |
T½ | 25 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by La Liga de la Leche, España of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
1st generation antihistamine, alkylamine derivative, with moderate sedative and antimuscarinic effects. Oral administration every 4 to 6 hours.
At the date of the last update we did not find published data on its excretion in breast milk.
Irritability, crying and insomnia have been described in an infant after the mother took a preparation that associated brompheniramine and isoephedrine, possibly responsible for the symptoms. (Mortimer 1977)
Monitor drowsiness and adequate feeding of the infant.
It has an antiprolactin effect that could inhibit lactation in the first weeks after delivery.
Due to its sedative effect, bed sharing with the infant is not recommended if this drug is being taken. (UNICEF 2018, 2017, 2017, 2014, 2014, 2013 and 2006, Landa 2012, ABM 2008)